Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia

Annals of Pharmacotherapy

Volumn 34, Issue 2, 2000, Pages 183-187

  Haroldson, Jeffrey A ^a   Kramer, Linda E ^b   Wolff, Denise L ^c   Lake, Kathleen D ^d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Duluth Clinic   (United States)

^c CNS Division   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Free fraction monitoring; Hypoalbuminemia; Valproic acid

Indexed keywords

VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GRAFT REJECTION; HEART FUNCTION; HEART TRANSPLANTATION; HUMAN; HYPOALBUMINEMIA; INTUBATION; LETHARGY; PRIORITY JOURNAL;

EID: 0033961749     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19147     Document Type: Article

References (25)

1. Levy RH, Schen DD. Valproate: absorption, distribution and excretion. In: Levy RH, Mattson R, Meldrum B, Penry JK, Dreifuss FE, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989:583-99.
2. MacKichan JJ. Influence of protein binding and the use of unbound (free) drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:5-1-5-48.
3. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72.
4. Levy RH, Wilensky AJ, Anderson GD. Carbamazepine, valproic acid, phenobarbital, and ethosuximide. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992;26-1-26-9.
5. Lenn JL, Robertson M. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology 1992;42:988-90.
6. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem 1998;44:1085-95.
7. Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit 1986;8:411-5.
8. Dasgupta A, Crossey M. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci 1997;313:75-9.
9. Patel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia 1979;20:85-90.
10. Gidal BE, Pitterle ME, Spencer NW, Maly MM. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther 1995;20:215-9.
11. Bowdle TA, Patel IH, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980;28: 486-92.
12. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994;105:602-4.
13. Toler SM, Wilkerson MA, Porter WH, Smith AJ, Chandler MHH. Severe phenytoin intoxication as a result of altered protein building in AIDS. DICP Ann Pharmacother 1990;24:698-700.
14. Driscoll DF, McMahon M, Blackburn GL, Bistrian BR. Phenytoin toxicity in a critically ill, hypoalbuminemic patient with normal serum drug concentrations. Crit Care Med 1988;16:1248-9.
15. Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 1973;14:177-84.
16. Peterson GM, Khoo BH, Von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991;13:415-9.
17. Svenson CK, Woodruff MN, Baxter JG, Lalka D. Free drug concentration monitoring in clinical practice: rationale and current status. Clin Pharmacokinet 1986;11:450-69.
18. Gidal B, Spencer N, Maly M, Pitterle M, Williams E, Collins M, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994;44:1418-22.
19. Gidal BE, Collins DM, Beinlich BR. Apparent valproic acid neurotoxicity in a hypoalbuminemic patient. Ann Pharmacother 1993;27:32-5.
20. Samara EE, Granneman RG, Witt GF, Cavanaugh JH. Effects of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol 1997;37:442-50.
21. Anderson GD, Gidal BE, Kantor ED, Wilensky AJ. Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia 1994;35:221-5.
22. Kaufman KR, Gerner R. Dose-dependent valproic acid thrombocytopenia in bipolar disorder. Ann Clin Psychiatry 1998;10:35-7.
23. Delgado MR, Riela AA, Mills J, Browne R, Roach ES. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994;9:311-4.
24. D'Angio RG, Stevenson JG, Lively BT, Morgan JE. Therapeutic drug monitoring: improved performance through educational intervention. Ther Drug Monit 1990;12:173-81.
25. Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW. Appropriateness of antiepileptic drug level monitoring. JAMA 1995;274:1622-6.